EDITAS MEDICINE INC.

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

11 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2021 Results and Update

05 May 2021 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

05 May 2021 06:59:00 By Nasdaq GlobeNewswire

Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting

04 May 2021 09:00:02 By Nasdaq GlobeNewswire

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting

01 May 2021 07:11:46 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

28 Apr 2021 07:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

25 Feb 2021 07:00:03 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

18 Feb 2021 16:02:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

08 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Pricing of Offering of Common Stock

20 Jan 2021 22:30:00 By Nasdaq GlobeNewswire